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STUDY PROTOCOL Open Access
Role of cerebral hypoperfusion in multiple
sclerosis (ROCHIMS): study protocol for a
proof-of-concept randomized controlled
trial with bosentan
Stéphanie Hostenbach1,2* , Ayla Pauwels1, Veronique Michiels1, Hubert Raeymaekers3, Anne-Marie Van Binst3,
Annick Van Merhaeghen-Wieleman1, Peter Van Schuerbeek3, Jacques De Keyser1,2,4 and Miguel D’Haeseleer1,2,5
Abstract
Background: Axonal degeneration is related to long-term disability in patients with multiple sclerosis (MS). The
underlying mechanism remains ill understood but appears to involve axonal energetic dysfunction. A globally
impaired cerebral blood flow (CBF) has been observed in the normal-appearing white matter (NAWM) of patients
with MS, which is probably related to astrocytic overexpression of endothelin-1 (ET-1). Cerebral hypoperfusion has
been associated with reduced mitochondrial activity and disabling symptoms (e.g. fatigue and cognitive decline) of
MS. Countering this process could therefore be beneficial in the disease course. Short-term CBF restoration with a
single 62.5-mg dose of the ET-1 receptor antagonist bosentan has already been demonstrated in patients with MS.
Methods: The ROCHIMS study is a proof-of-concept double-blind randomized clinical trial in which patients with
relapsing-remitting MS will receive either 62.5 mg bosentan or matching placebo twice daily during 28 ± 2 days.
Clinical evaluation and brain magnetic resonance imaging (MRI) will be performed at baseline and treatment
termination. Based on previous work, we expect a global increase of CBF in the individuals treated with bosentan.
The primary outcome measure is the change of N-acetyl aspartate in centrum semiovale NAWM, which is a marker
of regional axonal mitochondrial activity. Other parameters of interest include changes in fatigue, cognition, motor
function, depression, and brain volume.
Discussion: We hypothesize that restoring cerebral hypoperfusion in MS patients improves axonal metabolism.
Early positive effects on fatigue and cognitive dysfunction related to MS might additionally be detected. There is a
medical need for drugs that can slow down the progressive axonal degeneration in MS, making this an important
topic of interest.
Trial registration: Clinical Trials Register, EudraCT 2017-001253-13. Registered on 15 February 2018.
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Background
Multiple sclerosis (MS) is a chronic neurodegenerative
and inflammatory disorder of the central nerve system
(CNS) mainly affecting young adults [1]. Disease path-
ology is characterized by two key players: intermittent
bursts of focal inflammatory demyelination and wide-
spread progressive axonal degeneration. The clinical
course is highly variable. Most individuals start with a
relapsing-remitting pattern, in which newly formed
clinical deficits restore partially or completely over time,
but after several years they often develop a secondary
progressive phase of slower but continuous neurological
worsening. Other patients experience primary progres-
sive disease from onset [2].
MS relapses are triggered by the formation of focal
inflammatory lesions in which auto-immune reactions
against CNS myelin play a paramount role. In contrast,
the steadier decline mainly results from progressive
axonal loss [3]. The exact underlying mechanism of the
latter remains unclear and degenerative features do not
seem to correlate well with inflammatory activity, par-
ticularly in the later stages of the disease [4]. Recognition
is growing that mitochondrial energy failure and oxida-
tive stress are involved in this axonal degeneration
process of MS [5, 6]. Levels of N-acetylasparate (NAA),
an amino acid synthesized by mitochondria in neurons
and their axons, are a marker of both axonal mitochon-
drial activity and axonal integrity [7] and were found to be
reduced in several 1H-magnetic resonance spectroscopy
(MRS) studies of centrum semiovale normal-appearing
white matter (NAWM) in patients with MS compared to
controls [8].
Perfusion-weighted magnetic resonance imaging (MRI)
research conducted over the past decade has found that
cerebral blood flow (CBF) is globally impaired in the
NAWM of patients with relapsing-remitting MS (RRMS),
primary progressive MS, and even clinically isolated syn-
dromes suggestive for MS (CIS-MS) [9–11]. Similar obser-
vations have been made in the thalamus of CIS-MS and
RRMS individuals [12]. These findings suggest that
cerebral hypoperfusion is an early and integral feature of
MS pathology, regardless of the clinical subtype [5]. It is
unknown whether this phenomenon contributes to the
progressive loss of axons, but chronically induced cerebral
hypoperfusion in animal models leads to mitochondrial
energy failure, oxidative stress, and eventually axonal
degeneration [13]. In addition, reduced CBF has been
associated with cognitive dysfunction and fatigue in
patients with MS [14], which are both disabling but poorly
understood disease manifestations. Reduced cerebral per-
fusion in small rodents resulted in neuronal loss in the
hippocampal CA1 sub region, while MRI studies in MS
patients revealed selective and progressive hippocampal
atrophy localized initially to this CA1 sub region, which
may contribute, among other factors, to cognitive impair-
ment that occurs in many of these individuals [15, 16].
Reduced CBF in MS appears to be mediated by elevated
levels of the potent vasoconstrictive agent endothelin-1
(ET-1) in the cerebral circulation, most likely derived from
reactive astrocytes in focal lesions. In a previous study, the
administration of a single 62.5mg dose of bosentan, which
is an ET-1 receptor antagonist, increased CBF in patients
with MS up to the levels obtained in controls [5]. The
main goal of the present study is to investigate in NAWM
of patients with RRMS whether prolonged treatment with
bosentan results in a sustained restoration of CBF and
whether this enhances NAA levels, reflecting improve-
ment of axonal mitochondrial metabolism. Our secondary
aim is to explore whether CBF restoration ameliorates
clinical disability (fatigue, cognition, motor function, and
depression) and hippocampal volume in these patients.
Methods and design
Trial design
This study is a non-commercial proof-of-concept, placebo-
controlled, and double-blind randomized trial, taking place
at the Universitair Ziekenhuis (UZ) Brussel between Octo-
ber 2017 and December 2018. It is approved at national
level by the Federaal Agentschap Voor Geneesmiddelen en
Gezondheidsproducten (FAGG) and the local ethics com-
mittee of the UZ Brussel. The study is registered by the
European Union Drug Regulating Authorities (EudraCT
2017-001253-13) as the ROCHIMS (Role Of Cerebral Hy-
poperfusion In Multiple Sclerosis) trial. In case of protocol
modifications, all relevant stakeholders will be informed.
Eligibility criteria
All potential participants will be screened for study in-
clusion according to the criteria outlined below. Each
patient will be informed about the study protocol by the
principle investigator and written informed consent will
be obtained from all participants.
Inclusion criteria
 Age > 18 years;
 Diagnosis of relapsing-remitting MS, according to
the 2010 revised McDonald criteria [17];
 Expanded Disability Scale Score (EDSS) ≤ 4.0 [18];
 Use of reliable means of contraception for sexually
active female patients.
Exclusion criteria
 Clinical evidence of MS relapse within the last three
months before inclusion;
 Pregnant or lactating women;
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 Major liver dysfunction (AST and/or ALT > 3 times
ULN);
 Use of cyclosporine A or glibenclamide;
 Allergy to bosentan.
Randomization, study medication, and general outline
Participants will be randomly divided into a group re-
ceiving bosentan (Actelion Pharmaceuticals Ltd., Allsch-
wil, Switzerland) 62.5 mg twice daily and another group
receiving matching placebo, during 28 (± 2) days. The
randomization will be performed with “research
randomizer” (https://randomizer.org), using five sets
of six numbers in order to achieve an equal distribu-
tion between active product and placebo. Study medi-
cation will be stored at the Hospital Pharmacy. After
inclusion, patients are given a computer-generated
randomization number, which is matched to a confi-
dential treatment number by the responsible hospital
pharmacist in order to assign participants to either
bosentan or placebo.
Bosentan tablets are provided by Actelion Pharmaceu-
ticals Belgium NV (Mechelen, Belgium). The production
of identical-looking placebo tablets is performed by the
hospital pharmacy. The tablets are taken twice daily, at
08:00 and 20:00. Adherence to the study medication will
be assessed by counting the number of unused tablets
returned at the second visit. All adverse events will be
recorded in the “Adverse Event” section of the Case
Report Form. All methods for data collection and data
management will be collected in the Investigator Site
File. The data monitoring committee of this trial is the
Clinical Trial Centre of the University Hospital Brussel.
This Clinical Trial Centre works independent from the
sponsor and have no competing interests.
At baseline (day 0), patients will undergo a blood
analysis, clinical assessments, transcranial Doppler
(TCD), and brain MRI. All data will be pseudonymized.
Only the principle investigator has the key to source
data. Treatment will commence the next day (day 1). On














Blood Analyses (AST/ALT/NfL) x x
MRI brain x x
Transcranial Doppler x x
ASSESSMENTS:
Medical History x
Vital signs x x x







Side effects reviews x x
Fig. 1 ROCHIMS Trial time table. SPIRIT Figure. (See also list of abbreviations)
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tests will be performed between 09:00 and 13:00 to avoid
interference of fatigue accumulation during the day with
the results. Participants are asked to refrain from alcohol
or caffeine, as well as not to smoke, on the evaluation
days. Two weeks after ending the trial, participants will
be called to see whether any side effects has occurred in
that period. After closure of the study and unblinding,
only the individual patients will be informed about their
study medication and all biological specimens will be
destroyed. Communication of the study results will be
anonymized. The trial time table is presented in Fig. 1
(Additional file 1). The study protocol is constituted tak-
ing into account the SPIRIT guidelines; the SPRIT
checklist can be found as an attachment of this
manuscript.
Definition of outcome measures
Primary outcome
The primary outcome measure of the study is the
change in NAA/creatine (NAA/Cr) ratios in centrum
semiovale NAWM, measured with 1H-MRS as a part of
the MRI protocol, reflecting changes in axonal mito-
chondrial metabolism. Based on our previous findings, we
expect a rise of CBF values after treatment with bosentan
[5]. The MRI protocol contains a pseudo-continuous
arterial spin labeling (ASL) sequence to assess CBF in the
NAWM of the centrum semiovale.
Secondary outcomes
1. Changes in fatigue, cognition, symptoms of
depression, and motor function.
Clinical assessments will in each individual be per-
formed by the same trained MS study nurse or neurologist
in training to ensure consistency. They were trained in
advance by an internal senior staff member to perform the
neuropsychological assessments. Assessments are always
scheduled in the same order: fatigue and depression scales
and cognitive testing before motor function testing to
avoid the interference of physical fatigue with the results.
The assessments include the following:
1.1. Fatigue scales: Fatigue Severity Scale (FSS) [19],
Modified Fatigue Impact Scale – 5-item version
(MFIS-5) [20], and Fatigue Scale for Motor and
Cognitive functions (FSMC) [21]. These scales as-
sess the experienced severity of fatigue symptoms
and/or the impact on cognitive, physical, and psy-
chosocial functioning in the preceding four weeks.
1.2. Depressive symptomatology scales: Beck Depression
Inventory (BDI-II), which is a widely used to assess
the presence of symptoms of depression in the two
weeks preceding the questionnaire [22].
1.3. Cognitive performance scales: Brief International
Cognitive Assessment for Multiple Sclerosis
(BICAMS): SDMT (Symbol Digit Modality Test),
CVLT-II (California Verbal Learning Test), and
BVMT-R (Brief Visuospatial Memory Test-Revised).
The BICAMS is considered a brief and feasible tool
appropriate for the cognitive assessment of MS pa-
tients [23]. The SDMT is a test of information pro-
cessing speed with a high sensitivity to cognitive
impairment in MS, the CVLT-II is a test for
short-term and long-term verbal memory, and
the BVMT-R evaluates visuospatial memory
abilities [24].
1.4. Motor function testing: Timed 25 Foot Walk Test
(T25FWT) and 9-Hole Peg Test (9HPT). T25FWT
is a quantitative mobility and leg function perform-
ance test based on a timed 25-ft (or 7.62 m) walk.
The patient is instructed to walk as quick as pos-
sible, without running, and safely. The time needed
to perform this task, starts from the instruction
to start and ends when the patient reach the 25-ft
mark. Afterwards, the patient will walk the same
distance back. The average of these two times is the
score for the T25FWT. The 9-HPT is a quantitative
measure of upper extremity (arm and hand) func-
tion. Patients have to pick up nine little pegs one by
one from a container, put them as quickly as pos-
sible in nine empty holes, and once they are all in,
the patients have to replace them in the container
one by one. The total time for this is measured.
Patients have to perform this task twice with both
hands. The total score of the 9-HPT is the average
time of the four trials [25].
2. Brain volumetric changes will be investigated by
means of voxel-based morphometry (VBM) ana-
lysis, in which baseline T1-weighted images are
subtracted from analogue follow-up images, to
obtain images that represent changes of time for
each individual patient. Both hippocampal regions
will be selected as the main ROI for VBM
analysis.
3. Changes in serum levels of light chain
neurofilament (NfL).
Axonal damage has been associated with a release of
NfL, which is a compound of the axonal cytoskeleton,
into the cerebrospinal fluid (CSF) and peripheral blood
of patients with MS. New high-sensitive techniques
allow the detection of NfL differences at low
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concentration in the serum, which has the advantage of
being more easily accessible as CSF [26, 27].
4. Changes in cerebral hemodynamic parameters.
Cerebral circulation will additionally be assessed by
means of TCD, which is an easily applicable bedside
tool, for explorative reasons.
MRI protocol
All patients undergo a multimodal imaging protocol con-
sisting of a high-resolution anatomical scan (T1 3D
BRAVO, FOV= 256 × 256 × 180mm3, resolution = 1 × 1 ×
1mm3, TR = 8.5ms, TE = 3.2ms, flip angle = 12°, TI = 450
ms; sagittal scan orientation, axial and coronal reconstruc-
tions were made afterwards), 3D fluid-attenuated inver-
sion recovery (3D Cube T2 FLAIR, FOV = 256 × 256 ×
180mm3, resolution = 1 × 1 × 1mm3, TR = 8000ms, TE =
130ms, flip angle = 90°; sagittal scan orientation, axial and
coronal reconstructions were made afterwards) imaging,
ASL (3D ASL, FOV = 240 × 240mm3, spiral scan with 8
arms and 512 point per arm, 36 slices, slice thickness =
4.0 mm, TR = 4852ms, TE = 10.7ms, flip angle = 90°, TI =
2025ms; axial plane orientation) and 1H-MRS (MRS
PROBE, FOV = 20 × 20mm2, slice thickness = 10mm,
12 × 12 voxels, voxel thickness optimized per individual,
TR = 2000ms, TE = 144ms, NEX = 1.6) on a 3-T machine
(GE, MR 750W Discovery).
The regions of interest for CBF and NAA/Cr + PCr
quantification are the left and right centrum semiovale
NAWM. FLAIR images are used to avoid inclusion of
focal MS plaques. Brain volumetric changes after treat-
ment are investigated by VBM analysis using Statistical
Parametric Mapping 8 software. Total scanning time
takes about 30 min.
For anatomical reference, the axial reconstructed
T1-weighted BRAVO images were used; an EPISTAR
(echo-planar imaging and signal targeting with alternat-
ing radio-frequency) sequence is used. The slice orienta-
tion is transversal and imaging volume is centered on
the centrum semiovale. An EPI sequence with the same
parameters and orientation, but without labelling pulses,
is used to measure equilibrium magnetization. CBF is
calculated in the NAWM of the right and left centrum
semiovale by using a FLAIR scan to avoid placement in
plaques. Longitudinal relaxation rates for tissue (R1app)
was 0.91 s-1 and for blood (R1b) 0,59 s-1. The equilib-
rium magnetization of the white matter (M0WM) is
used to determinate the equilibrium magnetization of
blood (M0B). T2 relaxation times for white matter and
blood are 55 ms and 100 ms, respectively, which brings
us to the following relationship: M0B = 1.28 M0WM
[10]. The final CBF results represent the average of the
left and right centrum semiovale.
NAA is expressed as ratios to total creatinine (Cr, sum
of Cr, and PCr), measured by 1H-MRS. Total Cr is
supposed to maintain a relatively constant level [28]. A
two-dimensional (2D) spectroscopic imaging slab, which
contains multiple voxels of 1.5 cm3, is positioned in the
centrum semiovale above the corpus callosum. Water
suppressed single-slice-point-resolved spectroscopy is
used with the following scan parameters: TE = 144 ms;
TR = 2 s; slice thickness = 1.5 cm; in-plane resolution =
1 × 1 cm2; spectral band width = 2000 Hz, and 1024 sam-
ple points. NAA and Cr levels are analyzed in different
voxels in the NAWM of the centrum semiovale of both
cerebral hemispheres. Voxels including plaques and
black holes are excluded. Analysis of the spectroscopic
data is performed using GE Functool software, that
allows operator-independent quantification of NAA, Cr
+ PCr, and NAA/Cr + PCr ratios.
Blinding and statistical methods
Sample size calculation is based on the study of Steen et
al. where NAA/Cr in centrum semiovale NAWM was
10% lower in MS patients compared to healthy controls
[8]. The inclusion of 24 individuals has 90% power to
detect a 10% increase in NAA/Cr in centrum semiovale
NAWM in the bosentan group compared to the placebo
group, with a significance level of 0.05. Taking into
account asymptomatic efficiency loss (non-parametric
study of 5%) and potential drop outs of 5%, inclusion of
30 patients should be sufficient.
All study participants and investigators will remain
blinded throughout the complete treatment and evalu-
ation period. Unblinding will only be done after final
database lock or in case of emergencies and serious
adverse events.
All statistics will be performed by an independent bio-
metrician and with SPSS software, version 25. The
Wilcoxon signed-rank test for paired samples will be
used to compare differences within the two treatment
groups; the Mann–Whitney U test will be used to com-
pare differences between the groups. Fisher’s exact test
will be used to compare categorical variables. Spearman’s
correlation coefficient will be used to correlate continu-
ous data. The level for statistical significance is defined
as p < 0.05.
Discussion
Cerebral perfusion appears to be unequivocally and glo-
bally decreased in all subtypes of MS. Pathological reper-
cussions have hitherto received little attention but might
include fatigue, cognitive impairment, and contribution
to the hallmark process of axonal degeneration, possibly
by compromising mitochondrial energy production. In a
previous study, a single dose of 62.5 mg bosentan was
able to restore reduced CBF in patients with MS up to
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the levels measured in healthy controls, revealing a
potential new therapeutic target [5]. The ROCHIMS
study is the first proof-of-concept clinical trial evaluating
the effects of CBF restoration in patients with MS over a
longer treatment period. We hypothesize that countering
cerebral hypoperfusion in MS patients for one month
improves axonal metabolism, as reflected by NAA levels
measured with 1H-MRS. Beneficial effects may also be
noticeable on clinical (fatigue, cognition, motor function,
depression) and other imaging outcome parameters (hip-
pocampal volume).
There is a medical need for drugs that can halt or slow
down progressive axonal degeneration in MS. Repurpos-
ing drugs for proof-of-concept trials in this indication is
therefore of considerable interest. Bosentan is already
widely available for other medical conditions than MS
and the side effects, which in general are rather mild,
are well known. A limitation of this trial is the short
treatment period. The results of this proof-of-concept
trial will form the basis for further trials with a longer
period of treatment and more focused on clinical
outcome measures, especially progression of disability.
Trial status
The ROCHIMS study is currently recruiting patients.
The protocol “Versie 2.0 ROCHIMS” dated 16 August
2017 was approved by the FAGG and the local ethics
committee of the UZ Brussel. We started recruiting on
the first of September 2017 and will approximately end
the recruitment in April 2019.
Additional file
Additional file 1 : SPIRIT 2013 Checklist: Recommended items to
address in a clinical trial protocol and related documents. (DOC 122 kb)
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